340B Drug Pricing Program
AHA files reply brief as district court considers 340B payment remedy for the remainder of 2022.
The AHA weighs in on a number of issues of importance to hospitals and health systems, as well as the patients they care for, as they come before the court. Below are our most recent friend-of-the-court briefs.
The AHA Aug. 10 distributed to members a special bulletin encouraging hospitals to submit comments as soon as possible to the Centers for Medicare and Medicaid Services’ calendar year 2023 outpatient prospective payment system proposed rule.
The AHA Aug.
AHA yesterday asked the U.S. District Court for the District of Columbia to order the Department of Health and Human Services to immediately stop underpaying certain hospitals that participate in the 340B Drug Pricing Program and promptly repay them for the unlawful cuts since 2018 without…
The AHA today made a series of filings in district court to ensure that 340B hospitals are promptly repaid and that the rest of the hospital field is not penalized for the agency’s unlawful policy.
The Centers for Medicare & Medicaid Services (CMS) July 15 released its calendar year (CY) 2023 outpatient prospective payment system (OPPS) and ambulatory surgical center (ASC) proposed rule that would increase OPPS rates by a net 2.7% in CY 2023 compared to CY 2022.
For three decades, the 340B drug pricing program has enabled hospitals that serve high numbers of low-income patient populations to stretch scarce federal resources and provide more comprehensive care to their patients and communities.
The Centers for Medicare & Medicaid Services July 15 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system rates by a net 2.7% in calendar year 2023 compared to 2022.
Stacey Hughes
Executive Vice President
American Hospital Association
July 15, 2022